# Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy

> **NCT06870942** · PHASE2 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 35 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Radiotherapy

## Interventions

- **DRUG:** Maintenance first-line treatment plus radiation therapy

## Key facts

- **NCT ID:** NCT06870942
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-28
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06870942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06870942, "Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06870942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*